Novartis exec moves to J&J
Head of Novartis' North American pharmaceuticals unit Alex Gorsky resigns, the firm announces Feb. 14. Gorsky will join Johnson & Johnson as group chairman of the firm's medical device company Ethicon. Before joining Novartis in 2004 as Chief Operating Officer and Head of General Medicines, Gorsky served as company group chairman for J&J's pharmaceutical business in Europe, the Middle East and Africa. Gorsky will report to J&J Worldwide Chairman for Surgical Care Sheri McCoy...
You may also be interested in...
Ludwig Hantson becomes head of Novartis' North America pharma business, the company announces April 10. Hantson, who led Novartis' Specialty Medicines Operating Unit, replaces Alex Gorsky effective immediately (1"The Pink Sheet," Feb. 25, 2008, In Brief). Among other challenges, Hantson will have to determine the best course of action for Novartis' DPP-4 inhibitor Galvus (vildagliptin) following an approvable letter in 2007
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.